Abstract

Purpose To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome. Patients and Methods Consecutive BRAF-tested Australian patients with metastatic melanoma (n = 197) were observed prospectively. A comprehensive range of clinicopathologic variables were correlated with BRAF mutation status, and a survival analysis was conducted. Results Forty-eight percent of patients had a BRAF mutation; 70 patients (74%) had V600E, 19 (20%) had V600K, and six (6%) had other genotypes. Other than age at diagnosis of distant metastasis (median age, 56 v 63 years for BRAF-mutant v BRAF wild-type patients, respectively; P < .001), there was no significant difference in clinical features of patients with metastatic melanoma by mutation status. Features of the antecedent primary melanoma significantly associated with a BRAF mutation (P < .05) were histopathologic subtype, presence of mitoses, single or occult primary melanoma, truncal location, and age at diagnosis of primary tumor ≤ 50 years. The interval from diagnosis of first-ever melanoma to distant metastasis was not significantly different between BRAF-mutant and BRAF wild-type patients; however, the median survival of patients with newly diagnosed metastatic melanoma was 5.7 months for BRAF-mutant patients not treated with a BRAF inhibitor, 8.5 months for BRAF wild-type patients, and not reached for BRAF-mutant patients treated with a BRAF inhibitor. Conclusion V600K mutations comprised 20% of BRAF mutations. Characteristics of the antecedent primary melanoma and age at diagnosis differed in BRAF-mutant and BRAF wild-type patients. The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter.

Keywords

MedicineMelanomaV600EInternal medicineMetastasisOncologyVemurafenibMutationMetastatic melanomaCancer researchPathologyCancerBiologyGene

MeSH Terms

AdolescentAdultAge FactorsAgedAged80 and overAntineoplastic AgentsClinical TrialsPhase I as TopicClinical TrialsPhase II as TopicDNA Mutational AnalysisDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansKaplan-Meier EstimateLogistic ModelsMaleMelanomaMiddle AgedMutationNew South WalesOdds RatioPhenotypeProportional Hazards ModelsProspective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRisk AssessmentRisk FactorsSkin NeoplasmsTime FactorsTreatment OutcomeYoung Adult

Affiliated Institutions

Related Publications

Publication Info

Year
2011
Type
article
Volume
29
Issue
10
Pages
1239-1246
Citations
1027
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1027
OpenAlex
42
Influential
894
CrossRef

Cite This

Georgina V. Long, Alexander M. Menzies, Adnan Nagrial et al. (2011). Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. Journal of Clinical Oncology , 29 (10) , 1239-1246. https://doi.org/10.1200/jco.2010.32.4327

Identifiers

DOI
10.1200/jco.2010.32.4327
PMID
21343559

Data Quality

Data completeness: 86%